Search
forLearn
5 / 801 resultslearn Thymosin Beta 4
learn PTD-DBM
learn ACETYL TETRAPEPTIDE-2
learn acetyl tetrapeptide-3
Research
5 / 1000+ results
research The effects of GPR40 agonists on hair growth are mediated by ANGPTL4
GPR40 agonists help hair growth through the protein ANGPTL4.
research CD34 + cell–derived fibroblast-macrophage cross-talk drives limb ischemia recovery through the OSM-ANGPTL signaling axis
CD34+ cells help heal damaged limbs by promoting blood vessel growth.
research In vitro hair growth-promoting effects of araliadiol via the p38/PPAR-γ signaling pathway in human hair follicle stem cells and dermal papilla cells
Araliadiol may promote hair growth like minoxidil without being toxic.
research Resident CD34-positive cells contribute to peri-endothelial cells and vascular morphogenesis in salivary gland after irradiation
CD34-positive cells help repair and form new blood vessels in salivary glands after radiation.
research Megestrol Acetate Increases the Proliferation, Migration, and Adipogenic Differentiation of Adipose-Derived Stem Cells via Glucocorticoid Receptor
Megestrol acetate helps fat-derived stem cells grow, move, and turn into fat cells through a specific receptor.
Community Join
5 / 1000+ resultscommunity AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community PELAGE PHASE 2 TRIALS FOR PP405 - Volunteers Needed
PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.